5 Results for "

TG101348

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "TG101348" in MCE Product Catalog:

54
54 Cited Publications
Cat. No.: HY-10409
CAS No.: 936091-26-8
Purity:  99.83%
Synonyms: TG-101348; SAR 302503
Target:  

JAK Apoptosis

Research Areas:  

Cancer

Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .
loading...
    loading...
54
54 Cited Publications
Cat. No.: HY-10409A
CAS No.: 1374744-69-0
Purity:  99.92%
Synonyms: TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate
Target:  

JAK Apoptosis

Research Areas:  

Cancer

Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .
loading...
    loading...
Cat. No.: HY-10409R
CAS No.: 936091-26-8
Synonyms: TG-101348 (Standard); SAR 302503 (Standard)
Research Areas:  

Cancer

Fedratinib (Standard) is the analytical standard of Fedratinib. This product is intended for research and analytical applications. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .
loading...
    loading...
Cat. No.: HY-10409AR
CAS No.: 1374744-69-0
Synonyms: TG-101348 hydrochloride hydrate (Standard); SAR 302503 hydrochloride hydrate (Standard)
Research Areas:  

Cancer

Fedratinib (hydrochloride hydrate) (Standard) is the analytical standard of Fedratinib (hydrochloride hydrate). This product is intended for research and analytical applications. Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .
loading...
    loading...
Cat. No.: HY-10409S
Synonyms: TG-101348-d9; SAR 302503-d9
Fedratinib-d9 (TG-101348-d9) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .
loading...
    loading...